Published Date: 17 Mar 2023
NEW DELHI: The National Medical Commission (NMC) has requested all medical schools to schedule examination appointments for Broad...
Read Full NewsTrial data showed that treatment with lamotrigine reduced myotonia severity in adults with genetically confirmed non-dystrophic myotonias, with sustained benefit and an acceptable safety profile.
The neurologist in the Department of Neurology at Saratoga Hospital Medical Group shared what excites her most about the future of neurology, specifically for movement disorders, in 2026.
COPD Drug Withdrawal Tied to Early Exacerbation, With Alexander Mathioudakis, MD, PhD
FDA Accepts NDA for Priority Review of Centanafadine to Treat Adult, Pediatric ADHD
FDA Approves Labeling Update for iDose TR for Open-Angle Glaucoma and Ocular Hypertension
Apecotrep Delivers 40% Proteinuria Reduction in Phase 2 FSGS Trial
FDA Approves New Narcan Packaging, Aiming to Boost Carry Rates
1.
Q&A: When will individuals be able to receive customized cancer vaccines?
2.
There is a 40% reduction in the risk of 9 cancers with good cardiorespiratory fitness.
3.
AI Unlocks Benefits of Prostate Cancer Treatment.
4.
Q&A: How early cancer screening could save Canada nearly half a billion dollars over patients' lifetimes
5.
New study elucidates obesity's role in fueling breast cancer progression
1.
The Dark Side of Melanoma: Uncovering the Risk Factors and Prevention Strategies
2.
Unraveling the Mysteries of Metastasis: Exploring the Latest Advances in Cancer Research
3.
A New Hope: Exploring Treatment Options for Waldenstrom's Macroglobulinemia
4.
Molecular & Genetic Oncology: Emerging Frontiers in 2025
5.
The Millionaire's Battle: Does Mark Cuban Have Cancer?
1.
International Lung Cancer Congress®
2.
Future NRG Oncology Meeting
3.
Genito-Urinary Oncology Summit 2026
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Newer Immunotherapies for Myeloma- A Comprehensive Overview
2.
An In-Depth Look At The Signs And Symptoms Of Lymphoma- The Conclusion
3.
Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update) - Part V
4.
Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part V
5.
Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part II
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation